SEC Comment Letter 0000000000-24-003536 to Nascent Biotech Inc. (NBIO) (CIK 0001622057)
Nascent Biotech Inc. (NBIO) (CIK 0001622057)
Date: April 2, 2024 · CIK: 0001622057 · Accession: 0000000000-24-003536
AI Filing Summary & Sentiment
File numbers found in text: 333-277960
Letter
United States securities and exchange commission logo April 2, 2024 Sean Carrick Chief Executive Officer Nascent Biotech Inc. 623 17th Street Suite 4 Vero Beach, FL 32960 Re:Nascent Biotech Inc. Amendment No. 1 to Registration Statement on Form S-1 Filed March 29, 2024 File No. 333-277960 Dear Sean Carrick: We have reviewed your amended registration statement and have the following comments. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe a comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to this letter, we may have additional comments. Amendment No. 1 to Registration Statement on Form S-1 Cover Page 1.We note your response to prior comment 1 and reissue. Please revise your cover page to disclose the specific date that your best efforts offering will end, so that it is clear to investors when this offering will terminate. Refer to Item 501(b)(8)(iii) of Regulation S-K for guidance. Selling Security Holders, page 13 2.We do not see the revisions indicated in your response to prior comment 4. Please continue to revise your disclosure as requested by that comment.
FirstName LastNameSean Carrick Comapany NameNascent Biotech Inc. April 2, 2024 Page 2 FirstName LastName Sean Carrick Nascent Biotech Inc. April 2, 2024 Page 2 Please contact Tyler Howes at 202-551-3370 or Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Claudia J. McDowell, Esq.
Show Raw Text
United States securities and exchange commission logo
April 2, 2024
Sean Carrick
Chief Executive Officer
Nascent Biotech Inc.
623 17th Street Suite 4
Vero Beach, FL 32960
Re:Nascent Biotech Inc.
Amendment No. 1 to Registration Statement on Form S-1
Filed March 29, 2024
File No. 333-277960
Dear Sean Carrick:
We have reviewed your amended registration statement and have the following
comments.
Please respond to this letter by amending your registration statement and providing the
requested information. If you do not believe a comment applies to your facts and circumstances
or do not believe an amendment is appropriate, please tell us why in your response.
After reviewing any amendment to your registration statement and the information you
provide in response to this letter, we may have additional comments.
Amendment No. 1 to Registration Statement on Form S-1
Cover Page
1.We note your response to prior comment 1 and reissue. Please revise your cover page to
disclose the specific date that your best efforts offering will end, so that it is clear to
investors when this offering will terminate. Refer to Item 501(b)(8)(iii) of Regulation S-K
for guidance.
Selling Security Holders, page 13
2.We do not see the revisions indicated in your response to prior comment 4. Please
continue to revise your disclosure as requested by that comment.
FirstName LastNameSean Carrick
Comapany NameNascent Biotech Inc.
April 2, 2024 Page 2
FirstName LastName
Sean Carrick
Nascent Biotech Inc.
April 2, 2024
Page 2
Please contact Tyler Howes at 202-551-3370 or Tim Buchmiller at 202-551-3635 with
any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Claudia J. McDowell, Esq.